Cognition Therapeutics
Founded 2007 Β· 5 known investors
Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
BiotechHealthtech
Investors Β· 5
Non-dilutive funding Β· 12 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $1.6M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase IISTTR | 2018 | $2.1M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $360.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2017 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2017 | $224.1K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2016 | $224K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $222K |
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2015 | $298.5K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $142K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2010 | $198.4K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Cognition Therapeutics do?
- Cognition Therapeutics is a clinical-stage biotechnology company developing zervimesine (CT1812), an investigational once-daily oral small-molecule therapy designed to protect brain synapses by blocking toxic protein oligomers. It targets neurodegenerative diseases including dementia with Lewy bodies (DLB) and Alzheimer's disease.
- Who are Cognition Therapeutics's investors?
- Cognition Therapeutics's investors include 3E Bioventures Capital, Atlanta Technology Angels, Houston Angel Network, iNetworks, Dolby Family Ventures.